HSCT/Gene Therapy Co. Sees Many Positive Catalysts in Q422
Source: Yun Zhong  (8/15/22)
Hematopoietic stem cell transplantation (HSCT) and gene therapy firm Magenta Therapeutics Inc. recently announced updates related to two of its leading clinical programs. BTIG LLC advised in a research update that it expects Magenta to release updated clinical data from its MGTA-117 and MGTA-145 programs in Q4/22, which will serve as key catalysts for the company. BTIG stated it is reiterating its "Buy" rating and $6/share price target on Magenta Therapeutics. More >

Biotech Co. Nearing Milestones for HBV Drugs
Source: Ed Arce  (8/15/22)
Arbutus Biopharma Corp. presented clinical data to an international liver disease conference showing that its AB-729 continues to deliver strong reductions in HBsAg. The company is now conducting three separate combination therapy studies of its AB-729 and expects to achieve important milestones when the initial data readouts are released in H2/22. H.C. Wainwright & Co. affirmed its Buy rating for Arbutus Biopharma and adjusted its price target to $7.50. More >

Healthcare Co. Enters US Alcohol Addiction Treatment Market
Source: Streetwise Reports  (8/15/22)
One analyst says this healthcare co. has the opportunity to generate attractive CAPEX-light, high margin SaaS-like recurring revenues, which investors are currently getting for free, after the biotech firm entered the US market for alcohol addiction treatment through off-label licensing deals with a network of treatment clinics. More >

Expert Expects Life Science Co. To Do Exceptionally Well
Source: Penny Queen  (8/15/22)
Avivagen is an early-stage life sciences company with a patented product for immune support that causes dramatic and profitable improvements in livestock. They have been increasing their sales and market penetration at a dramatic rate, and I believe them to be at an inflection point. Research coverage is expecting a 7x return.
More >

Firm Sees Boost in Sales of Health Chewable for Dogs
Source: Joseph Gomes   (8/15/22)
Recent orders from Avivagen Inc. are helping the developer of this product build a recurring revenue stream, noted a Noble Capital Markets report. More >

Diagnostics Co. Secures Global Deal for Resistant Bacteria ID Kit
Source: Streetwise Reports  (8/15/22)
Accelerate Diagnostics Inc. shares traded 25% higher after the company reported Q2/22 earnings and announced it entered into a commercial agreement with Becton, Dickinson and Co. that will allow it to deliver rapid antimicrobial identification and susceptibility diagnostics to clinicians and patients worldwide. More >

Feedstock Additive Co. Gets Massive Order for Brazil Market
Source: Streetwise Reports  (8/11/22)
The widespread use of antibiotics in animal feeds, as well as over-prescription by physicians for therapeutic treatment of human infections, is leading to a growing resistance to antibiotics that is killing close to 1 million people each year. One company believes it has developed at least part of the solution through a beta carotene food additive that boosts immunity and contributes to better overall health. More >

Testing Confirms Drug Candidate Differs From Peers
Source: Dr. Douglas Loe  (8/10/22)
Biotech ProMIS Neurosciences Inc.'s monoclonal antibody in development for Alzheimer's disease boasts a "unique" binding profile that could be "important to its clinical success," noted a Leede Jones Gable report. More >

Demand for Co.’s Antibiotic Free Animal Feed Is Raising
Source: Clive Maund  (8/10/22)
With consumers moving away from artificial meat products and other preservatives, Avivagen Inc.'s antibiotic free animal feed seems to be just what they're looking for. With orders coming in and demand raising, expert Clive Maund shares his view on the potential of this life science company. More >

Pharma Co. Achieves Record Sales of LEMS Drug in Q2
  (8/10/22)
Shares of Catalyst Pharmaceuticals Inc. traded 24% higher to a new 52-week high after the company reported that in Q2/22 net product revenues from sales of its FIRDAPSE® increased 57.7% YoY to $53.0 million. FIRDAPSE® has been approved by both the U.S. FDA and Health Canada as a treatment for adult patients with Lambert-Eaton myasthenic syndrome, a rare autoimmune disease in which a person's immune system attacks its body's own tissues at the neuromuscular junction. More >

Cardiovascular Device Co. On Pace to Double Revenue in FY22
Source: Streetwise Reports  (8/9/22)
Shares of Shockwave Medical Inc. traded 17% higher to a new 52-week high after the company advised that it posted a 116% YoY increase in revenue during Q2/22 and raised the midpoint for its FY/22 revenue guidance by $25 million to $465-475 million. More >

Biotech Co. Awakes To Good News
Source: Clive Maund  (8/6/22)
Awakn Life Sciences Corp.'s rating went to an Immediate Speculative Buy after it received substantial funding from the UK government. Expert Clive Maund shares his thoughts on the development. More >

Biopharma Co. Planning BLA for DMD Drug
Source: Yun Zhong, Ph.D.  (8/5/22)
Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy. Equity research firm BTIG LLC advised in a research update that SRP-9001 seems to have met the necessary criteria for receiving accelerated approval and it expects an AdCom will be established shortly. BTIG stated that it rates Sarepta Therapeutics as a "Buy" and has a $125 price target for the company's shares. More >

SRT Device Maker's Revenues Rise 124% in Q2
Source: Streetwise Reports  (8/5/22)
Sensus Healthcare Inc.'s shares traded 30% higher after the company reported it achieved a 124% YoY increase in revenue in Q2/22. The company advised that demand continues to remain strong for its superficial radiation therapy (SRT) devices which provide minimally invasive and non-surgical alternatives for non-melanoma skin cancer & keloid removal. More >

Environmental Tech Co. Builds up to a Major Bull Market
Source: Clive Maund  (8/4/22)
After a few weeks of observation, expert Clive Maund believes Bion Environmental Technologies Inc. may be due for a major uptrend and is building up to a major bull market. More >

Ins. Provider to Offer Med Tech Co.'s CGM to its 45M Members
Source: Streetwise Reports  (8/4/22)
Shares of Senseonics Holdings Inc. traded 31.5% higher yesterday after the company reported that Elevance Health (formerly Anthem) has approved coverage of its Eversense® E3 implantable continuous glucose monitor to its forty-five million covered members. More >

ChemoCentryx Shares Double on $4B Cash Bid from Amgen
Source: Streetwise Reports  (8/4/22)
Shares of ChemoCentryx Inc. traded 110% higher after the company reported it agreed to be acquired by Amgen Inc. for $52.00 per share in an all-cash deal valued at $4 billion. With the purchase, Amgen aims to cement its leadership position in inflammation and nephrology with the addition of ChemoCentryx's TAVNEOS® (avacopan) which the U.S. FDA approved late last year to treat ANCA-associated vasculitis, a serious autoimmune disease. More >

MRI Device Maker's Earnings Come In at High End of Forecasts
Source: Streetwise Reports  (8/3/22)
IRadimed Corp. reported Q2/22 financial results that were modestly higher than expected. ROTH Capital Partners LLC advised in a research update that based on the company's higher revenues, improved margins and disciplined cost control measures it is maintaining its Buy rating on IRadimed and raising its price target to $42/share (up from $40). More >

Expert Says Biotech Co. Is a ‘Strong Buy’ After Phase 2 Study
Source: Clive Maund  (8/2/22)
Expert Clive Maund gives his assessment of biotech Algernon Pharmaceuticals Inc. after its Phase 2 study of Ifenprodil. More >

Expert Believes Health Co. Blooms With Opportunity
Source: Clive Maund  (8/2/22)
Expert Clive Maund touches on the latest news with Bloom Health Partners Inc. from the enthusiastic buying toward the end of June to whether he believes the health company is still bullish. More >

Tech Co. ‘Right at the Point of Breakout'
Source: Clive Maund  (8/2/22)
BioLargo Inc. seemed to be very close to breaking out of its tight trading range on July 20, 2022, after remaining in the same place for a month. Expert Clive Maund goes over this update and his assessment of the company after this news. More >

Study Review Shows Greater Promise for Biopharma Co.'s Cough Treatment
Source: Andre Uddin  (8/1/22)
After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company. More >

Drug Candidate Repairs Motor/Sensory Function in Stroke
Source: Streetwise Reports  (7/29/22)
Shares of NervGen Pharma Corp. traded 28% higher yesterday after the company reported that, in a landmark pre-clinical animal study, its NVG-291-R demonstrated significant functional repair to damage from ischemic stroke seven days following the event. More >

Additional Study Review Reveals Patients Coughed Much Less
Source: Streetwise Reports  (7/28/22)
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought. More >

Biotech Co. Granted New Patent for Breast Cancer Vaccine
  (7/27/22)
Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology. H.C. Wainwright & Co. LLC advised that this action strengthens the company's IP portfolio and therefore it is reiterating its Buy rating on Anixa. More >